https://jamanetwork.com en-us Sat, 01 Jun 2024 00:00:00 GMT Wed, 19 Jun 2024 10:52:43 GMT Silverchair [email protected] [email protected] https://jamanetwork.com/journals/jamadermatology/fullarticle/2817890 Sat, 01 Jun 2024 00:00:00 GMT This consensus statement uses the Delphi process to develop a core domain set for rosacea clinical trials and practice. 160 6 658 666 10.1001/jamadermatol.2024.0636 2817890 https://jamanetwork.com/journals/jamadermatology/fullarticle/2817742 Sat, 01 Jun 2024 00:00:00 GMT While many treatments are available for papules and pustules of rosacea, few are available for erythema and flushing. The 2019 Global Rosacea Consensus Panel recommends general skincare, β-blockers (eg, propranolol and carvedilol), and α-adrenergic agents (eg, brimonidine and oxymetazoline) for flushing and vascular lasers for persistent erythema. Because these treatments may not always be effective or tolerated, there remains an unmet need for additional options that can address symptoms of flushing and erythema in rosacea. 160 6 620 620 10.1001/jamadermatol.2024.0397 2817742 https://jamanetwork.com/journals/jamadermatology/fullarticle/2817738 Sat, 01 Jun 2024 00:00:00 GMT This nonrandomized controlled trial analyzes the efficacy and safety of erenumab, an anti–calcitonin gene-related peptide receptor monoclonal antibody, for rosacea-associated erythema and flushing. 160 6 612 619 10.1001/jamadermatol.2024.0408 2817738